Every analysis.

The headline is the negotiated price. The story is who controls the channel — and this week the pan-Canadian Pharmaceutical Alliance quietly redrew the map for everyone holding inventory.

Dropping the contentious price tests looks like an industry victory. The second-order effect on launch sequencing is the part worth watching.

Read the reimbursement conditions as an opening negotiating position, not a clinical verdict — and watch who blinks first.

Notice of Compliance is the starting gun, not the finish line. Here's how the next 18 months of switching policy likely plays out.